gMG

Argenx (ARGX) reported Q3 2025 global product net sales of $1.13B and total operating income of $1.15B. Operating profit reached $346M, with $4.3B in cash and financial assets. The company reaffirmed its ~$2.5B combined R&D and SG&A guidance and plans to file an sBLA for seronegative gMG by year-end 2025, with ADAPT-OCULUS results expected in 1H26. Five registrational readouts are anticipated in 2026. A FUJIFILM manufacturing partnership expanded with a new North Carolina site.